CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population [PDF]
Frontiers in Pharmacology, 2017 Purpose: Asian populations have around 40–60% frequency of reduced function allele CYP2D6∗10 compared to 1–2% in Caucasian populations. The wide range of CYP2D6 enzyme activities in subjects with the CYP2D6∗10 variant is a big concern for clinical ...
Pei Hu, Rui Chen, Xin Zheng
doaj +2 more sources
Duloksetins betydning for serumkonsentrasjonen av psykofarmaka som omsettes via CYP2D6 [PDF]
, 2009 Bakgrunn: Duloksetin er et relativt nytt antidepressivum som hemmer reopptak av serotonin og noradrenalin intersynaptisk. Det metaboliseres via Cytokrom P450 2D6 (CYP2D6) og CYP1A2, men antas også å være en svak/moderat hemmer av CYP2D6.
Enoksen, Torill Bakko
core +2 more sources
Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]
, 2020 Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher +8 more
core +1 more source
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. [PDF]
, 2011 Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and ...
Baak-Pablo, Renee F +8 more
core +2 more sources
Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan [PDF]
Clinical Pharmacology & Therapeutics, 2010 The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability.
Abduljalil, K +8 more
openaire +3 more sources
Pharmacogenetics of ophthalmic topical β-blockers [PDF]
, 2008 Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A. +4 more
core +1 more source
Physicochemical and biopharmaceutical characterization of new sulfonamide derivatives of gallic acid
British Journal of Pharmacy, 2022 Gallic acid (GA) is known for its antioxidant activity which is restricted due to its low oral permeability. In this project the carboxylic group of (GA) was substituted with sulfonamide group and hydroxyl groups were methylated which resulted ...
Dania Hussein Alhyari +7 more
doaj +1 more source
Physiology-based IVIVE predictions of tramadol from in vitro metabolism data [PDF]
, 2014 To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (SimcypA (R)).
Allegaert, Karel +10 more
core +1 more source
Frontiers in Pharmacology, 2023 CYP2D6 is one of the most polymorphic drug-metabolizing enzymes in the liver. While genetic CYP2D6 variants serve as clinical biomarkers to predict CYP2D6 activity, large inter-person variability in CYP2D6 expression remains unaccounted for.
Joseph M. Collins +3 more
doaj +1 more source